SHANGHAI, China, Jan. 11 /Xinhua-PRNewswire/ -- Sundia MediTech (Shanghai) Company recently announced a welcome addition of new members to its executive team: Dr. Joseph Zhu and Dr. Shu Gao. Dr. Zhu is appointed as the Vice President of Medicinal Chemistry, while Dr. Gao as the Vice President in charge of Chemical Synthesis business.
According to the company announcement, Dr. Zhu got his college education in chemistry in Nanjing University in China. After research work in China for a few years, he left the country for graduate study in the United States and obtained his PhD degree from Colorado State University in 1995. Later he joined the chemistry research and discovery team at Amgen, a giant in pharmaceutical industry, garnering 10 years of experience in the fields of new drug development and management. Two months ago, Dr. Zhu decided to leave his career in US and move to Shanghai with his family to join Sundia.
Dr. Gao received his PhD degree from the Institute of Organic Chemistry in Shanghai in 1995, and in the same year he went to Canada to pursue his post doctorate training. Upon completing his program, he joined Canada's largest CRO company, MDS Pharma Services Inc, and gathered bountiful working experience in pharmaceutical CRO services for 5 years. In 2003, Dr. Gao accepted a professorship offer from Jilin University in Changchun, China. He joined Sundia in 2004, right after the formation of the company. For the past 3 years, Dr. Gao progressed step by step from the company's chemistry research director, to executive director, and now to vice president.
According to Sundia's CEO Dr. Xiaochuan Wang, the company's CRO service business has been growing at an amazing rate. Last year alone, their revenue increased more than 150%. To match this rapid expansion in both business scope and size, the company is constantly adding outstanding personnel to its executive management team. In early 2007, the company headhunted Mr. Beijia Yu from a Fortune 500 multinational company in US to take the company's CFO position. Mr. Yu had an excellent track record in corporate financial management from his long term career in United States. "I am very happy to see so many high level talents to join our effort in Sundia. That will greatly help Sundia to become a leading player in the global CRO market". Said Dr. Wang.
About the company:
Sundia MediTech was founded in Shanghai in 2004 by a group of veterans of the US pharmaceutical industry to provide drug discovery and development CRO services. Seeing the rapidly developing global CRO industry, the founders left their positions in the US and came to China to start their own company. Over the past 3 years, Sundia has thrived and built a strong reputation in its field. Following a 2007 merger with neighbor United PharmaTech, Sundia looks forward to continuing its phenomenal growth rate.
|SOURCE Sundia MediTech (Shanghai) Company|
Copyright©2008 PR Newswire.
All rights reserved